We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.45%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.57B
AUM Growth
-$289M
Cap. Flow
-$161M
Cap. Flow %
-6.26%
Top 10 Hldgs %
55.83%
Holding
95
New
7
Increased
6
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$265M
2
RLAY icon
Relay Therapeutics
RLAY
+$43.5M
3
FATE icon
Fate Therapeutics
FATE
+$28.3M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$16.3M
5
PMVP icon
PMV Pharmaceuticals
PMVP
+$13.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$89.2M
2
ARGX icon
argenx
ARGX
+$51.6M
3
CNTB
Connect Biopharma Holdings
CNTB
+$50.4M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$43.7M
5
FULC icon
Fulcrum Therapeutics
FULC
+$35.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.19%
2 Miscellaneous 11.98%
3 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQRX
51
DELISTED
EQRx, Inc. Common Stock
EQRX
$6.82M 0.26%
+1,000,000
New +$9.44M
BCEL
52
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.67M 0.26%
2,202,333
– –
ODT
53
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$5.68M 0.22%
4,207,086
-1,400,000
-25% -$3.31M
SLDB icon
54
Solid Biosciences
SLDB
$897M
$5.56M 0.22%
211,847
-37,125
-15% -$1.13M
ELEV
55
DELISTED
Elevation Oncology
ELEV
$5.25M 0.2%
872,780
-468,750
-35% -$3.24M
BLSA
56
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.9M 0.19%
500,000
– –
RACB
57
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.88M 0.19%
500,000
– –
JYAC
58
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.88M 0.19%
500,000
– –
PANA
59
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.85M 0.19%
500,000
– –
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$4.61B
$4.32M 0.17%
+185,000
New +$3.72M
OBIO icon
61
Orchestra BioMed
OBIO
$363M
$4.03M 0.16%
400,000
– –
MLTX icon
62
MoonLake Immunotherapeutics
MLTX
$1.04B
$3.96M 0.15%
400,000
– –
IRON icon
63
Disc Medicine
IRON
$2.58B
$3.78M 0.15%
43,333
– –
DBVT
64
DBV Technologies
DBVT
$739M
$3.42M 0.13%
213,460
-540,000
-72% -$18.3M
ORIC icon
65
Oric Pharmaceuticals
ORIC
$1.28B
$2.94M 0.11%
200,000
– –
CABA icon
66
Cabaletta Bio
CABA
$441M
$2.05M 0.08%
540,000
-1,063,361
-66% -$11.3M
OMEG
67
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.95M 0.08%
200,000
– –
TARA icon
68
Protara Therapeutics
TARA
$222M
$1.41M 0.05%
209,227
– –
GNCA
69
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.32M 0.05%
1,134,453
– –
SRZN icon
70
Surrozen
SRZN
$209M
$1.29M 0.05%
13,333
– –
NUVB.WS
71
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$504K 0.02%
266,666
– –
ARGX icon
72
argenx
ARGX
$61.3B
– –
-170,926
Closed -$51.6M
ASMB icon
73
Assembly Biosciences
ASMB
$532M
– –
-125,000
Closed -$5.22M
CLRB icon
74
Cellectar Biosciences
CLRB
$21.9M
– –
-3,067
Closed -$851K
CNTB
75
Connect Biopharma Holdings
CNTB
$73.7M
– –
-2,081,323
Closed -$50.4M
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Boxer Capital held 95 positions worth $2.57B, down 10% from $2.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital withdrew a net $161M in Q4 2021, closing 24 positions and reducing 12 holdings. Its most notable exit was argenx, an estimated $51.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Boxer Capital opened a new position in State Street SPDR S&P Biotech ETF worth $246M.

  • Boxer Capital's largest Q4 2021 buy was State Street SPDR S&P Biotech ETF: 2,200,000 shares worth $246M.
  • Boxer Capital added most to Relay Therapeutics in Q4 2021, an estimated $43.5M increase.
  • Boxer Capital's biggest Q4 2021 reduction was BeOne Medicines Ltd, cutting an estimated $89.2M.
  • Boxer Capital fully exited argenx in Q4 2021, selling an estimated $51.6M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.57B portfolio in Q4 2021.
  • Boxer Capital opened 7 new positions and closed 24 in Q4 2021.
  • Boxer Capital's portfolio value fell 10% quarter-over-quarter to $2.57B.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.